Achieve Life Sciences, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-16$5.83 RISE2026-03-27$2.65 PEAK2026-05-12$5.99 116d | -54.5% 70d | Missed | Missed | — | — | +126.0% 46d | Missed |
DROP2026-01-16$5.83 RISE2026-02-05$3.95 PEAK2026-04-17$5.10 91d | -32.2% 20d | Missed | Missed | — | — | +29.1% 71d | Missed |
DROP2025-10-30$5.24 RISE2025-11-20$3.88 PEAK2026-01-16$5.83 78d | -26.0% 21d | Missed | Missed | — | — | +50.3% 57d | Missed |
DROP2025-06-03$4.21 RISE2025-08-12$2.44 PEAK2025-10-30$5.24 149d | -42.0% 70d | Missed | Missed | — | — | +114.8% 79d | Missed |
DROP2025-06-03$4.21 RISE2025-07-07$2.07 PEAK2025-08-25$3.31 83d | -50.8% 34d | Missed | Missed | — | — | +59.9% 49d | Missed |
DROP2024-12-09$4.56 RISE2025-04-08$1.98 PEAK2025-06-03$4.21 176d | -56.6% 120d | Missed | Missed | — | — | +112.6% 56d | Missed |
DROP2024-10-08$5.27 RISE2025-01-21$2.85 PEAK2025-02-10$3.53 125d | -45.9% 105d | Missed | Missed | — | — | +23.9% 20d | Missed |
DROP2024-06-04$5.50 RISE2024-09-05$4.16 PEAK2024-10-08$5.27 126d | -24.4% 93d | Missed | Missed | — | — | +26.7% 33d | Missed |
DROP2023-12-01$5.84 RISE2024-04-12$4.35 PEAK2024-06-04$5.50 186d | -25.5% 133d | Missed | Missed | — | — | +26.4% 53d | Missed |
DROP2023-11-28$5.86 RISE2024-02-22$3.82 PEAK2024-05-15$5.21 169d | -34.8% 86d | Missed | Missed | — | — | +36.4% 83d | Missed |
DROP2023-11-28$5.86 RISE2023-12-12$3.15 PEAK2024-01-25$5.14 58d | -46.2% 14d | Missed | Missed | — | — | +63.2% 44d | Missed |
DROP2023-06-14$6.30 RISE2023-10-19$3.65 PEAK2023-11-28$5.86 167d | -42.1% 127d | Missed | Missed | — | — | +60.5% 40d | Missed |
DROP2023-05-10$9.93 RISE2023-07-06$4.88 PEAK2023-07-13$5.70 64d | -50.9% 57d | Missed | Missed | — | — | +16.8% 7d | Missed |
DROP2023-02-14$5.80 RISE2023-03-13$4.28 PEAK2023-05-10$9.93 85d | -26.2% 27d | Missed | Missed | — | — | +132.0% 58d | Missed |
DROP2022-08-18$5.00 RISE2022-12-27$2.42 PEAK2023-02-14$5.80 180d | -51.6% 131d | Missed | Missed | — | — | +139.7% 49d | Missed |
1–15 / 28 1 / 2 | |||||||
Achieve Life Sciences (ACHV) downgraded to Hold as FDA CRL risk delays cytisinicline NDA to Q4 2026. Read the latest analysis on the stock here.
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter results following the recent appointment of Dr. Andrew Goldberg as CEO and a material capital raise. In its report, management reiterated expectations that it will receive a Complete Response Letter (CRL) and affirmed its intent to resubmit a New Drug
Achieve Life Sciences Inc (ACHV) secures significant capital and partners with Adare Pharma Solutions, setting the stage for a promising commercial launch in 2027.
Achieve Life Sciences Inc (ACHV) secures significant capital and partners with Adare Pharma Solutions, setting the stage for a promising commercial launch in 2027.
Moby summary of Achieve Life Sciences, Inc.'s Q1 2026 earnings call
Moby summary of Achieve Life Sciences, Inc.'s Q1 2026 earnings call
Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027. Dr. Andrew Goldbe
Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027. Dr. Andrew Goldbe
Achieve Life Sciences reports Q1 2026 EPS of -$0.19, beating estimates, alongside a $354M private placement and new CEO appointment for cytisinicline development.
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call May 12, 2026 8:30 AM EDTCompany ParticipantsNicole Jones - Vice President of Strategic...
Presentation Operator MessageOperator Greetings, and welcome to the Achieve Life Sciences First Quarter 2026 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this...
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Ohtuvayre®, one of the most successful specialty pharmaceutical launches in recent industry historySEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the gl
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q26 Earnings Webcast. Al
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 May 05, 2026 8:30am EDT Download as PDF ...
In our monthly Rare Stock Picks series, we're highlighting April 2026 investment picks. Click here for the list of April 2026 Buy recommendations.
Corporate Presentation April 2026 Transforming public health and delivering shareholder value 1 Cytisinicline, as a first...
By John Vandermosten, CFA NASDAQ: ACHV Achieve Life Sciences, Inc. (NASDAQ: ACHV) generated significant news flow in April, announcing the arrival of a new CEO, substantial new financing, and a cytisinicline manufacturing update. On April 15 th , Achieve indicated that it had completed cytisinicline’s technology transfer to Adare Pharma Solutions in Vandalia, Ohio. The shift in manufacturers
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACHV | +19.63% | +13.42% | +5.43% | +46.37% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +16.67% | +19.13% | +8.88% | +33.68% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 588.6K | $1.73M | 0.00% | Trimmed-21.4% | 2026-03-31 |
| StateStreet | passive | 254.5K | $748.10K | 0.00% | Added+8.6% | 2026-03-31 |
| Citadel | multi-strat | 37.8K | $111.01K | 0.00% | Trimmed-49.8% | 2026-03-31 |
| RenTech | quant | 28.0K | $82.18K | 0.00% | Trimmed-81.7% | 2026-03-31 |
| FidelityFMR | fundamental | 5.9K | $17.33K | 0.00% | Trimmed-9.5% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-13 | Martin Christopher Nathan | Director | A Grant / award(deriv) | 47,250 | — | +$0 |
| 2026-04-21 | Goldberg Andrew D. | CEO and President | A Grant / award(deriv) | 11,706,270 | — | +$0 |
| 2026-04-21 | Goldberg Andrew D. | CEO and President | A Grant / award(deriv) | 3,601,929 | — | +$0 |
| 2026-04-21 | Goldberg Andrew D. | CEO and President | A Grant / award(deriv) | 1,800,965 | — | +$0 |
| 2026-01-30 | Wan Jerry | Principal Accounting Officer | A Grant / award(deriv) | 70,300 | — | +$0 |
| 2026-01-30 | Stewart Richard Alistair | Chief Executive Officer | A Grant / award(deriv) | 645,000 | — | +$0 |
| 2026-01-30 | Donnelly Craig | Chief Operations Officer | A Grant / award(deriv) | 180,000 | — | +$0 |
| 2026-01-30 | Xinos Jaime | Chief Commercial Officer | A Grant / award(deriv) | 180,000 | — | +$0 |
| 2026-01-30 | Oki Mark K | Chief Financial Officer | A Grant / award(deriv) | 180,000 | — | +$0 |
| 2026-01-30 | Rubinstein Mark Lawrence | Chief Medical Officer | A Grant / award(deriv) | 180,000 | — | +$0 |
| 2025-12-08 | Atkisson Erik | Chief Legal Officer | A Grant / award(deriv) | 250,000 | — | +$0 |
| 2025-10-03 | Donnelly Craig | Chief Operations Officer | A Grant / award(deriv) | 50,000 | — | +$0 |
| 2025-09-22 | Stewart Richard Alistair | Chief Executive Officer | M Option exercise(deriv) | 157,500 | — | +$0 |
| 2025-09-22 | Stewart Richard Alistair | Chief Executive Officer | M Option exercise(deriv) | 140,000 | — | +$0 |
| 2025-09-22 | Stewart Richard Alistair | Chief Executive Officer | S Open-market sale | 129,501 | $2.92 | −$378.1K |
| 2025-09-22 | Stewart Richard Alistair | Chief Executive Officer | M Option exercise | 297,500 | — | +$0 |
| 2025-09-22 | Oki Mark K | Chief Financial Officer | M Option exercise(deriv) | 168,000 | — | +$0 |
| 2025-09-22 | Oki Mark K | Chief Financial Officer | S Open-market sale | 50,060 | $2.92 | −$146.2K |
| 2025-09-22 | Oki Mark K | Chief Financial Officer | M Option exercise | 168,000 | — | +$0 |
| 2025-09-08 | Xinos Jaime | Chief Commercial Officer | M Option exercise(deriv) | 20,000 | — | +$0 |
| 2025-09-08 | Xinos Jaime | Chief Commercial Officer | M Option exercise(deriv) | 49,000 | — | +$0 |
| 2025-09-08 | Xinos Jaime | Chief Commercial Officer | S Open-market sale | 20,854 | $2.77 | −$57.8K |
| 2025-09-08 | Xinos Jaime | Chief Commercial Officer | M Option exercise | 69,000 | — | +$0 |
| 2025-09-08 | JACOBS CINDY | President & CMO | M Option exercise(deriv) | 26,000 | — | +$0 |
| 2025-09-08 | JACOBS CINDY | President & CMO | M Option exercise(deriv) | 84,000 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.15 | — | — |
| 2026-05-12 | -0.30 | -0.19 | +36.36% |
| 2026-03-24 | -0.28 | -0.28 | -1.20% |
| 2025-11-06 | -0.26 | -0.28 | -7.69% |
| 2025-08-07 | -0.35 | -0.37 | -4.52% |
| 2025-05-13 | -0.37 | -0.37 | -1.17% |
| 2025-03-11 | -0.36 | -0.36 | — |
| 2024-11-07 | -0.29 | -0.36 | -25.00% |
| 2024-08-13 | -0.24 | -0.25 | -5.93% |
| 2024-05-09 | -0.25 | -0.26 | -3.31% |
| 2024-03-28 | -0.32 | -0.26 | +18.75% |
| 2023-11-09 | -0.37 | -0.34 | +7.61% |
| 2023-08-14 | -0.41 | -0.43 | -4.88% |
| 2023-05-09 | -0.69 | -0.50 | +27.11% |
| 2023-03-16 | -0.95 | -0.83 | +12.32% |
| 2022-11-14 | -1.13 | -1.35 | -19.82% |